Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 6/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.43 |
| ▸ | TERT | O14746 | 2/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19662620 | 0.83 | GRIN1 (0.47) | GRIN1GRIN2AGRIN2BBRD4TERT | |
| SCHEMBL21787242 | 0.80 | SMYD3 (0.49) | GRIN1GRIN2AGRIN2BTERTSMYD3 | |
| SCHEMBL3265291 | 0.76 | KDM4E (0.60) | GRIN1GRIN2AGRIN2BALDH1A1 | |
| SCHEMBL14159023 | 0.75 | CYP1A2 (0.63) | GRIN1GRIN2AGRIN2BALDH1A1 | |
| SCHEMBL27262549 | 0.73 | MAPT (0.53) | ALDH1A1 | |
| SCHEMBL16151772 | 0.73 | SMN1; SMN2 (0.69) | GRIN1GRIN2AGRIN2BTERT | |
| SCHEMBL17623623 | 0.73 | HDAC3 (0.59) | GRIN1GRIN2AGRIN2BALDH1A1 | |
| SCHEMBL27328060 | 0.72 | SMN1; SMN2 (0.52) | GRIN1GRIN2AGRIN2BTERT | |
| SCHEMBL28131346 | 0.71 | NPC1 (0.44) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL16428996 | 0.71 | SMN1; SMN2 (0.67) | GRIN1GRIN2AGRIN2BTERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | POLRMT, RNGTT, MTR | GRIN1 4613/4885GRIN2A 4278/4885GRIN2B 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.